First person vaccinated during trial of new Ebola jab
Oxford University has begun human clinical trials for a new vaccine targeting the Bundibugyo strain of Ebola. The vaccine, developed in just eight weeks, is being tested on healthy volunteers to assess safety and efficacy.
Why it matters
Represents a significant advancement in rapid vaccine development for rare and deadly viral outbreaks.
A volunteer was injected on Friday with the first dose of a rapidly developed vaccine targeting the Bundibugyo strain of Ebola driving a deadly outbreak in the Democratic Republic of Congo, Oxford University said.
More than 1,270 people have been killed out of nearly 3,000 infections in the DRC and Uganda since the outbreak emerged in May, according to the most recent figures from the World Health Organization.
Researchers and health organisations have since been racing to get a vaccine or treatment for the relatively rare strain to the clinical trial stage where it is tested on humans.
Earlier this month, a team at Oxford University in the UK announced it was launching the first trial for its ChAdOx1 BDBV vaccine, which uses the same technology as AstraZeneca's Covid-19 vaccine.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in